



Supplementary Figure 11 | Functional regulation of AR activity by *HORAS5*. (A,B) Relative expression (qPCR) of (A) *MYC* or (B) *HPRT1* mRNA in LNCaP treated with either *HORAS5*-targeting or control siRNA (5nM for 24h), followed by treatment with the transcriptional inhibitor Actinomycin-D (20uM) for increasing durations. (C) Relative expression (qPCR) of mature (exonic) or premature (intronic) AR RNA in LNCaP cells treated with either control or *HORAS5*-targeting siRNA (5nM) for 72h. * $p < 0.05$; **** $p < 0.0001$ (two-way ANOVA and Tukey's test). (D) BART transcription factor prediction results of genes either negatively or positively correlated with *HORAS5* expression in the TCGA PCa tumors ($n=499$; data accessed through cBioportal). AR is highlighted in red.